ETAKAFUSP ALFA
UNII 5Y27P3LNU6
Substance Identification & Data
This profile provides standardized clinical and technical data for Etakafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5Y27P3LNU6.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2852680-28-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
5Y27P3LNU6
2852680-28-3
N/A
Detailed Substance Profile
Preferred Name
ETAKAFUSP ALFA
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
12919
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
NO-57
Identifier assigned by the United States Adopted Names Council.
Substance Type
Etakafusp Alfa
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Etakafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Etakafusp Alfa
Common Names & Synonyms
ETAKAFUSP ALFA [USAN]
Etakafusp alfa [WHO-DD]
Humanized immunoglobulin G1-kappa anti-(human CD8) fused at the C-terminus of one heavy chain, via peptide linker 449SGGGGSGGGGSGGGGS464, to a variant of human interleukin-2, glycoform alfa; gamma 1 heavy chain (1-448) [VH (Homo sapiens IGHV1-69*01 - (IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31-35.50-66.99-108)) (1-119) -Homo sapiens IGHG1*03v (CH1 (120-217), hinge (218-232), CH2 L236>A, L237>A, G239>A (233-342), CH3 S356>C, T368>S, L370>A, Y409>V (343-447), CHS K449>del (448)) (120-448)] fused via a peptide linker 449SGGGGSGGGGSGGGGS464 to human interleukin-2 (IL-2, T-cell growth factor (TCGF) fragment 21-153, [H16>E480,R38>E502, F42>A506, C125>A589]-variant (1-133, 465-597 in the current sequence), (222-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'':356-351'')-trisdisulfide with gamma 1 heavy chain (1''-449'') [VH (Homo sapiens IGHV1-69*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31''-35''.50''-66''.99''-108'')) (1''-119'') -Homo sapiens IGHG1*03v (CH1 (120''-217''), hinge (218''-232''), CH2 L236''>A, L237''>A, G239''>A (233''-342''), CH3 Y351''>C, T368''>W (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-214''')-disulfide with kappa light chain (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'''-34'''.50'''-56'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (108'''-214''')]; produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Immunoglobulin G1 [236-alanine,237-alanine,239-alanine,356-cysteine,368-serine,370-alanine,409-valine,de-449-lysine], anti-(human CD8 antigen) (human-Mus musculus monoclonal AB248 γ1-chain) fusion protein with peptide linker ((SGGGG)3S) fusion protein with interleukin 2 [16-glutamic acid,38-glutamic acid,42-alanine,125-alanine] (human), (228→228′),(231→231′),(356→351′)-tris(disulfide) with immunoglobulin G1 [236-alanine,237-alanine,239-alanine,351-cysteine,368-tryptophan] anti-(human CD8 antigen) (human-Mus musculus γ1-chain), disulfide with human-Mus musculus monoclonal AB248 κ-chain, dimer
etakafusp alfa [INN]
gamma 1 heavy chain (1-448) [VH (Homo sapiens IGHV1-69*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31-35.50-66.99-108)) (1-119) -Homo sapiens IGHG1*03v (CH1 (120-217), hinge (218-232), CH2 L <sup>236</sup> >A, L <sup>237</sup> >A, G<sup>239</sup> >A (233-342), CH3 S <sup>356</sup> >C, T<sup>368</sup> >S, L <sup>370</sup> >A, Y <sup>409</sup> >V (343-447), CHS K <sup>449</sup> >del (448)) (120-448)] fused via a peptide linker <sup>449</sup> SGGGGSGGGGSGGGGS <sup>464</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF) fragment 21-153, [H <sup>36</sup> >E <sup>480</sup> , R<sup>58</sup> >E <sup>502</sup> , F <sup>62</sup> >A <sup>506</sup> , C<sup>145</sup> >A <sup>589</sup> ]-variant (1-133, 465-597 in the current sequence), (222-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'':356-351'')-trisdisulfide with gamma 1 heavy chain (1''-449'') [VH (Homo sapiens IGHV1-69*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31''-35''.50''-66''.99''-108'')) (1''-119'') -Homo sapiens IGHG1*03v (CH1 (120''-217''), hinge (218''-232''), CH2 L <sup>236''</sup> >A, L <sup>237''</sup> >A, G<sup>239''</sup> >A (233''-342''), CH3 Y <sup>351''</sup> >C, T<sup>368''</sup> >W (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-214''')-disulfide with kappa light chain (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'''-34'''.50'''-56'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (108'''-214''')]; produced in Chinese hamster ovary (CHO) cells, glycoform alfa antineoplastic
humanized immunoglobulin G1-kappa anti-(human CD8) fused at the C-terminus of one heavy chain, via peptide linker <sup>449</sup> SGGGGSGGGGSGGGGS<sup>464</sup>, to a variant of human interleukin-2, glycoform alfa
Technical Codes
AB-248
AB248
